טוען...
Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
Severe asthma affects between 5% and 10% of patients with asthma worldwide and requires best standard therapies at maximal doses, but there is a subgroup of patients refractory to all treatments. We share a case report of a 53-year-old woman with a history of severe allergic asthma that progressivel...
שמור ב:
| הוצא לאור ב: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5687776/ https://ncbi.nlm.nih.gov/pubmed/29184413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S149775 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|